4PD in vivo MDSC/Mφ Transfection Kit
4PD in vivo transfection kit is a nanocarrier for the selective drug delivery to and transfection of myeloid-derived suppressor cells (MDSCs) and macrophages (Mφ) in vivo.
Highlights:
- 4PD is a G5 PAMAM dendrimer conjugated to a peptide specifically targeted to MDSCs and tumor associated macrophages
- The kit allows for transfection of primary human MDSC and macrophages
- Nucleic acids can be delivered in vivo, eliminating the need to isolate and enrich MDSCs
- The kit allows the simultaneous in vivo delivery of multiple nucleic acids to MDSCs and macrophage
- Simple and quick procedure; nucleic acids or drugs and dendrimer selfassemble into active complex in five minutes
- The low immunogenicity of the optimize formulation allows multiple administration without the induction of neutralizing antibody
- The use of 4PD in conjunction with BrUTP allows to follow the fate of transfected cells by flow cytometry.
- Quality Controlled - Each lot is tested in vivo for its ability to preferentially transfect myeloid cells using AF555-control shRNA and ex vivo flow cytometry analysis
Myeloid-Derived Suppressor Cells (MDSCs) and tumor-associated macrophages (Mφ) are emerging as the most important pro-tumoral populations present in tumor host. These cells play a key role in promoting tumor progression and metastasis as well as in inhibiting spontaneous or therapeutically induced anti-tumor immunity. The 4PD nanoparticle is a G5 PAMAM dendrimer functionalized with a peptides recognizing receptors on MDCSs and macrophages. The formulation has been optimized with the use of amphipathic molecules that increase specificity and reduce the immunogenicity of the nanoparticle. Nucleic acids (e.g., DNA, RNA, shRNA), small molecules, drugs, etc. are loaded onto the dendrimer and the amphipathic molecule is added to reduce immunogenicity. 4PD has been shown effective in specifically targeting and delivering nucleic acids to MDSCs and serves as a useful tool for detection or the modulation of gene expression.
From the laboratory of Paolo Serafini, PhD, University of Miami.
4PD in vivo transfection kit is a nanocarrier for the selective drug delivery to and transfection of myeloid-derived suppressor cells (MDSCs) and macrophages (Mφ) in vivo.
Highlights:
- 4PD is a G5 PAMAM dendrimer conjugated to a peptide specifically targeted to MDSCs and tumor associated macrophages
- The kit allows for transfection of primary human MDSC and macrophages
- Nucleic acids can be delivered in vivo, eliminating the need to isolate and enrich MDSCs
- The kit allows the simultaneous in vivo delivery of multiple nucleic acids to MDSCs and macrophage
- Simple and quick procedure; nucleic acids or drugs and dendrimer selfassemble into active complex in five minutes
- The low immunogenicity of the optimize formulation allows multiple administration without the induction of neutralizing antibody
- The use of 4PD in conjunction with BrUTP allows to follow the fate of transfected cells by flow cytometry.
- Quality Controlled - Each lot is tested in vivo for its ability to preferentially transfect myeloid cells using AF555-control shRNA and ex vivo flow cytometry analysis
Myeloid-Derived Suppressor Cells (MDSCs) and tumor-associated macrophages (Mφ) are emerging as the most important pro-tumoral populations present in tumor host. These cells play a key role in promoting tumor progression and metastasis as well as in inhibiting spontaneous or therapeutically induced anti-tumor immunity. The 4PD nanoparticle is a G5 PAMAM dendrimer functionalized with a peptides recognizing receptors on MDCSs and macrophages. The formulation has been optimized with the use of amphipathic molecules that increase specificity and reduce the immunogenicity of the nanoparticle. Nucleic acids (e.g., DNA, RNA, shRNA), small molecules, drugs, etc. are loaded onto the dendrimer and the amphipathic molecule is added to reduce immunogenicity. 4PD has been shown effective in specifically targeting and delivering nucleic acids to MDSCs and serves as a useful tool for detection or the modulation of gene expression.
From the laboratory of Paolo Serafini, PhD, University of Miami.
| Product Type: | Kit |
| Name: | 4PD in vivo MDSC/Mφ Transfection Kit |
| Components: |
Component 1: 4PD Component 2: Enhancing solution Component 3: 10X buffer Component 4: Endotoxin/RNAse-free water |
| Tested Applications: |
Transfection of primary human MDSCs and macrophages Transfection reagent to study complex MDSC pathways in vivo Regulation of gene expression in MDSCs in vivo and in vitro Therapeutic delivery platform to reverse tumor-mediated immunosuppression Following the fate of transfected cells by flow cytometry |
| Number of Transfections: | Sufficient material for 30 injections of 10ug of RNA in mice |
| Molecule Delivered: | Nucleic acids (e.g., DNA, RNA, shRNA), small molecules, drugs |
| Injection Route: | Systemic delivery (Tail vein, intravenous, intraperitoneal injection), Local injection |
| Particle Size: | 60-100nm (fully loaded) |
| Storage: | -20C >1 year |
| Shipped: | Dry ice |
- Serena Zilio, Jennifer L. Vella, Adriana C. De la Fuente, Pirouz M. Daftarian, Donald T. Weed, Angel Kaifer, Ilaria Marigo, Kevin Leone, Vincenzo Bronte, Paolo Serafini. 4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. The Journal of Immunology April 10, 2017, 1600833; DOI: 10.4049/jimmunol.1600833.
If you publish research with this product, please let us know so we can cite your paper.
